Global Rapid Influenza Diagnostic Test (RIDT) Market Size By Type (Digital RIDTs, Conventional RIDT), By Application (Hospitals, POCT), By Region, And Segment Forecasts, 2023 to 2032

The Global Rapid Influenza Diagnostic Test (RIDT) Market was valued at USD 1.8 billion in 2023 and is projected to reach USD 3.6 billion by 2031, growing at a CAGR of 9.0% during the forecast period from 2023 to 2031. This growth is driven by the increasing prevalence of seasonal and pandemic influenza outbreaks, rising awareness of early detection methods, and expanding point-of-care diagnostic applications globally. RIDTs offer quick results (typically within 15–30 minutes), making them vital tools in clinics, hospitals, and emergency settings for timely influenza management and reducing transmission.

Drivers:

1. Rising Global Influenza Burden:

Annual influenza epidemics lead to millions of severe illnesses and thousands of deaths globally. Governments and healthcare systems are increasingly focusing on early detection and containment, spurring the demand for RIDTs.

2. Growing Point-of-Care Diagnostics Demand:

The healthcare sector’s shift toward decentralized testing and near-patient diagnostic tools is accelerating the adoption of RIDTs, especially in outpatient, home care, and remote settings.

3. Technological Advancements in RIDTs:

Innovations such as digital readouts, improved antigen detection sensitivity, and multiplex testing formats are enhancing the reliability and accuracy of RIDTs, thereby boosting market confidence.

Restraints:

1. Limited Sensitivity Compared to Molecular Tests:

Despite their speed, RIDTs have comparatively lower sensitivity, leading to potential false negatives, especially in adults. This diagnostic limitation can hinder market growth in favor of molecular assays.

2. Regulatory and Reimbursement Challenges:

Differences in national regulatory approvals and inconsistent reimbursement policies may limit the widespread adoption of RIDTs, especially in developing healthcare systems.

Opportunity:

1. Expanding Application in Pandemic Preparedness:

Governments are integrating RIDTs into pandemic response protocols for early influenza detection and outbreak control. This provides significant growth opportunities for manufacturers involved in public health tenders and preparedness stockpiles.

2. Emerging Markets Growth:

Countries in Asia-Pacific, Latin America, and parts of Africa are experiencing increased demand for rapid diagnostics due to healthcare infrastructure development and disease surveillance efforts, offering lucrative expansion potential for RIDT providers.

Market by System Type Insights:

Lateral Flow Assays accounted for the largest market share in 2023 due to their simplicity, low cost, and rapid turnaround time. These tests are widely adopted in primary care and emergency departments. Meanwhile, digital RIDTs are gaining momentum, especially in developed markets, thanks to enhanced sensitivity, connectivity, and automated result interpretation.

Market by End-Use Insights:

Hospitals & Clinics dominated the market in 2023, accounting for over 50% of total revenue, owing to their essential role in acute respiratory infection diagnosis and treatment initiation. However, retail pharmacies and diagnostic labs are emerging as fast-growing segments, supported by increasing public access to healthcare and over-the-counter testing kits.

Market by Regional Insights:

North America led the global RIDT market in 2023, fueled by strong healthcare infrastructure, high influenza testing rates, and supportive government health programs. Asia-Pacific is forecast to be the fastest-growing region during 2023–2031, driven by large populations, rising healthcare investments, and increasing awareness of rapid diagnostic tools.

Competitive Scenario:

Key players in the Global RIDT Market include QuidelOrtho Corporation, Becton, Dickinson and Company, Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Meridian Bioscience, Sekisui Diagnostics, bioMérieux, Luminex Corporation, and Access Bio Inc. These companies are focusing on strategic partnerships, FDA approvals, and product innovations to enhance their global footprint.

Key Developments:

2023: QuidelOrtho launched Sofia® 3 Flu+, a digital immunofluorescence assay with enhanced multiplexing capabilities.

2024: Abbott expanded its BinaxNOW™ rapid test platform in Asia-Pacific through local manufacturing partnerships.

2025: Roche Diagnostics received CE mark approval for a next-generation digital RIDT offering enhanced sensitivity and connectivity for integrated health systems.

Scope of Work – Global Rapid Influenza Diagnostic Test (RIDT) Market

Report Metric Details

Market Size (2023) USD 1.8 Billion

Projected Market Size (2031) USD 3.6 Billion

CAGR (2023–2031) 9.0%

Market Segments By System Type (Lateral Flow, Digital), End-Use, Region

Growth Drivers Increasing influenza cases, demand for rapid POC testing

Opportunities Expansion in emerging markets, pandemic preparedness

FAQs:

1) What is the current market size of the Global Rapid Influenza Diagnostic Test (RIDT) Market?

The market size was valued at USD 1.8 billion in 2023.

2) What is the major growth driver of the Global Rapid Influenza Diagnostic Test (RIDT) Market?

The major driver is the rising demand for rapid point-of-care influenza diagnostics due to increasing flu cases and pandemic preparedness efforts.

3) Which is the largest region during the forecast period in the Global Rapid Influenza Diagnostic Test (RIDT) Market?

North America is expected to remain the largest region during the forecast period.

4) Which segment accounted for the largest market